Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models

Wang, Ergang; Xiang, Kun; Zhang, Yun; Wang, Xiaofan

doi:10.1016/j.jncc.2022.10.001

Cited by 22 publications

(9 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PDO xenografts are reported to better represent the cancer cell state of the parental tumor, and thus serve as more effective models for drug testing. They can be easily genetically modified, allowing for broad applications in basic cancer research and show a higher success rate as compared to PDX models at a more reasonable time and cost (for a more comprehensive review on this see [ 70 ]).…”

Section: Discussionmentioning

confidence: 99%

Pancreatic Cancer Organoids: An Emerging Platform for Precision Medicine?

2023

View full text Add to dashboard Cite

Despite recent therapeutic advances, pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies, with remarkable resistance to treatment, poor prognosis, and poor clinical outcome. More efficient therapeutic approaches are urgently needed to improve patients’ survival. Recently, the development of organoid culture systems has gained substantial attention as an emerging preclinical research model. PDAC organoids have been developed to study pancreatic cancer biology, progression, and treatment response, filling the translational gap between in vitro and in vivo models. Here, we review the rapidly evolving field of PDAC organoids and their potential as powerful preclinical tools that could pave the way towards precision medicine for pancreatic cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Pancreatic Cancer Organoids: An Emerging Platform for Precision Medicine?

2023

View full text Add to dashboard Cite

show abstract

“…These PDOs play a crucial role in developing individualized treatment strategies by cultivating a patient’s own tumor cells, which accurately represent the specific genetic and molecular properties of their cancer. This precision approach not only enhances treatment efficacy but also reduces side effects and the use of ineffective medications ( Wang et al, 2022a ; Zeng et al, 2023 ). Evidence strongly supports the use of PDOs for pre-treatment testing, as studies have shown higher response rates and improved survival outcomes compared to conventional treatments that do not consider individual variability ( Yahng et al, 2017 ; Wensink et al, 2021 ).…”

Section: Personalized Medicine and Patient-derived Organoidsmentioning

confidence: 99%

The future of cancer therapy: exploring the potential of patient-derived organoids in drug development

Avci,

Bagca,

Shademan

et al. 2024

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Cancer therapy is on the brink of a significant transformation with the inclusion of patient-derived organoids (PDOs) in drug development. These three-dimensional cell cultures, directly derived from a patient’s tumor, accurately replicate the complex structure and genetic makeup of the original cancer. This makes them a promising tool for advancing oncology. In this review, we explore the practical applications of PDOs in clinical drug screening and pharmacognostic assessment, as well as their role in refining therapeutic strategies. We provide insights into the latest advancements in PDO technology and its implications for predicting treatment responses and facilitating novel drug discoveries. Additionally, we address the operational challenges associated with incorporating PDOs into the drug development process, such as scaling up organoid cultures, ensuring consistent results, and addressing the ethical use of patient-derived materials. Aimed at researchers, clinicians, and key stakeholders in oncology, this article aims to succinctly present both the extraordinary potential and the obstacles to integrating PDOs, thereby shedding light on their prospective impact on the future of cancer treatment.

show abstract

“…These models have lately been expanded to transplant organoid and tumoroid lines into animals as allografts and xenografts. Importantly, the pathological and invasive features of the original tumor and drug response of the patient are retained in these models, providing a suitable alternative to investigate mechanisms of malignant transformation, tumor plasticity, and metastasis in vivo [236].…”

Section: Modeling Of Tumor Biologymentioning

confidence: 99%

A systematic review on the culture methods and applications of 3D tumoroids for cancer research and personalized medicine

Kalla,

Pfneissl,

Mair

et al. 2024

Cell Oncol.

View full text Add to dashboard Cite

Cancer is a highly heterogeneous disease, and thus treatment responses vary greatly between patients. To improve therapy efficacy and outcome for cancer patients, more representative and patient-specific preclinical models are needed. Organoids and tumoroids are 3D cell culture models that typically retain the genetic and epigenetic characteristics, as well as the morphology, of their tissue of origin. Thus, they can be used to understand the underlying mechanisms of cancer initiation, progression, and metastasis in a more physiological setting. Additionally, co-culture methods of tumoroids and cancer-associated cells can help to understand the interplay between a tumor and its tumor microenvironment. In recent years, tumoroids have already helped to refine treatments and to identify new targets for cancer therapy. Advanced culturing systems such as chip-based fluidic devices and bioprinting methods in combination with tumoroids have been used for high-throughput applications for personalized medicine. Even though organoid and tumoroid models are complex in vitro systems, validation of results in vivo is still the common practice. Here, we describe how both animal- and human-derived tumoroids have helped to identify novel vulnerabilities for cancer treatment in recent years, and how they are currently used for precision medicine.

show abstract

Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models

Cited by 22 publications

References 133 publications

Pancreatic Cancer Organoids: An Emerging Platform for Precision Medicine?

Pancreatic Cancer Organoids: An Emerging Platform for Precision Medicine?

The future of cancer therapy: exploring the potential of patient-derived organoids in drug development

A systematic review on the culture methods and applications of 3D tumoroids for cancer research and personalized medicine

Contact Info

Product

Resources

About